The U.S. dry eye disease diagnostic devices market is expected to witness steady growth through 2031, supported by the rising prevalence of dry eye disease, an aging population, increasing exposure to digital screens, and continued technological advancements in ophthalmic diagnostic equipment. The market was valued at approximately US$58.3 million in 2020 and is projected to reach US$99.4 million by the end of 2031, expanding at a compound annual growth rate (CAGR) of 4.4% from 2021 to 2031.

Dry eye disease is among the most common ocular conditions encountered by ophthalmologists in the U.S. Its multifactorial nature can make diagnosis and management challenging, creating demand for technologies capable of providing more detailed and objective assessments of the ocular surface, tear film, cornea, and meibomian glands.

The market includes a broad range of diagnostic technologies, including anterior segment optical coherence tomography (AS-OCT), meibography devices, corneal topographers, osmolarity testing devices, ocular surface thermographers, interferometers, fluorophotometers, and other diagnostic systems.

Rising Prevalence of Dry Eye Disease Supports Market Growth

The increasing prevalence and incidence of dry eye disease in the U.S. represent key factors driving demand for diagnostic devices. According to the market information, an American Journal of Ophthalmology study estimated overall dry eye disease prevalence in the U.S. at 5.28% between 2003 and 2015, while prevalence can vary considerably depending on the population and risk factors examined.

Age is also an important factor. The prevalence of dry eye disease increases with advancing age, creating additional demand for diagnostic services as the U.S. population becomes older.

The growing geriatric population is therefore expected to remain an important market driver. Older adults can face a higher risk of ocular surface disorders, encouraging ophthalmologists and healthcare providers to adopt technologies that support timely identification and evaluation of dry eye conditions.

Increased Digital Device Use Raises Eye Health Awareness

The widespread use of smartphones, computers, tablets, televisions, and other video display terminals (VDTs) has increased attention toward digital eye health. Prolonged screen exposure can be associated with changes in blinking behavior and ocular discomfort, contributing to concerns surrounding dry eye symptoms.

The expansion of remote work and digital communication has further increased daily screen exposure for many individuals. This has encouraged greater awareness of ocular surface health and may contribute to demand for diagnostic evaluations.

Healthcare providers and med-tech companies are responding by expanding access to diagnostic tools and exploring new models of eye care, including telehealth and eHealth services.

Meibography Emerges as an Important Diagnostic Technology

Meibography is gaining increasing attention in the U.S. dry eye disease diagnostic devices market because of its ability to provide detailed imaging of the meibomian glands.

Meibomian gland dysfunction (MGD) is an important contributor to evaporative dry eye disease. High-definition meibography systems enable ophthalmologists to examine the structure and condition of the glands and identify abnormalities that may otherwise be difficult to assess.

The non-invasive nature of meibography makes it an attractive tool for ocular surface evaluation. As awareness of MGD increases, manufacturers are expected to continue developing imaging systems that provide higher-resolution visualization, improved usability, and more efficient clinical workflows.

AS-OCT Advances Ocular Surface Imaging

Anterior segment optical coherence tomography is another important technology contributing to market development. AS-OCT enables fast, non-contact, in-vivo imaging of structures within the anterior segment of the eye.

The technology is attracting attention for its potential to provide detailed information about corneal structures and other ocular features. As clinicians seek more objective approaches to dry eye evaluation, advances in AS-OCT could support broader use of imaging-based diagnostic techniques.

Researchers and med-tech companies are also investigating ways to combine imaging with advanced analytical methods to improve diagnostic performance.

Artificial Intelligence Creates New Opportunities

The absence of a universally accepted gold-standard diagnostic test for dry eye disease presents an ongoing challenge for clinicians. This has encouraged companies and researchers to explore artificial intelligence and deep learning technologies that can potentially improve diagnostic accuracy and consistency.

Deep learning models can be trained to identify patterns within ophthalmic images and other diagnostic information. In the context of AS-OCT and ocular surface assessment, such technologies may help distinguish dry eye patients from healthy individuals and support more standardized clinical evaluations.

AI-enabled diagnostic devices could ultimately provide clinicians with additional tools for interpreting complex ocular data. Continued research and validation will be important to determine how effectively these technologies can complement established clinical assessment methods.

Corneal Topography Supports Preoperative Assessment

Corneal topography is another important technology within the market. This computer-assisted examination evaluates the shape and surface characteristics of the cornea by projecting illuminated rings onto the corneal surface and analyzing their reflection.

Dry eye can influence corneal measurements and potentially affect visual symptoms and higher-order aberrations. Consequently, corneal topography can provide valuable information when assessing patients, including individuals being considered for refractive surgery.

Manufacturers are continuing to improve corneal topographers to provide detailed measurements and support efficient ophthalmic workflows.

Ocular Surface Thermography Gains Attention

Ocular surface thermography is emerging as another technology with potential applications in dry eye evaluation. Advances in thermographic systems have improved the ability to measure ocular surface temperature in real time.

Compared with older infrared thermography approaches, newer ocular surface thermographers are being developed to provide greater precision and potentially more useful information regarding ocular surface status.

As clinicians seek additional objective indicators for evaluating ocular surface disorders, thermographic technologies could create new opportunities within the diagnostic device market.

Market Segmentation

Based on device type, the U.S. dry eye disease diagnostic devices market includes AS-OCT, meibography devices, corneal topographers, osmolarity testing devices, ocular surface thermographers, interferometers, fluorophotometers, and others.

By disease, the market is divided into evaporative dry eye syndrome and aqueous dry eye syndrome.

Based on end-user, the market includes hospitals, diagnostic centers, ophthalmology centers and clinics, and other healthcare facilities.

The availability of multiple diagnostic technologies allows healthcare providers to select devices according to clinical requirements, patient characteristics, diagnostic objectives, and healthcare setting.

Technology Innovation Remains Central to Market Development

Technological advancement is expected to remain one of the most important factors influencing the market through 2031. Dry eye disease can have multiple causes and manifestations, creating a need for diagnostic approaches capable of assessing different aspects of ocular surface health.

Manufacturers are therefore focusing on improving imaging quality, automation, accuracy, speed, and ease of use. Integration of artificial intelligence, advanced imaging, and digital data analysis could further enhance diagnostic workflows.

The development of non-invasive and patient-friendly diagnostic technologies may also encourage broader adoption across ophthalmology practices and diagnostic centers.

Competitive Landscape

The U.S. dry eye disease diagnostic devices market features several prominent medical technology and ophthalmology companies. Key players identified in the market include Johnson & Johnson Services, Inc., OCULUS Optikgeräte GmbH, Carl Zeiss Meditec AG, TearLab Corporation, Optovue, Inc., AXIM Biotechnologies, Topcon Corporation, Quantel Medical, Essilor Instruments, I-MED Pharma, Inc., Box Medical Solutions Inc., and NIDEK CO., LTD.

Companies are focusing on product innovation, research and development, advanced imaging technologies, diagnostic accuracy, and expanded clinical applications to strengthen their positions.

Outlook

Overall, the U.S. dry eye disease diagnostic devices market is expected to maintain a positive growth trajectory through 2031. Rising disease prevalence, population aging, increasing exposure to digital devices, and growing awareness of ocular surface disorders are expected to support demand.

At the same time, innovations in meibography, AS-OCT, corneal topography, thermography, interferometry, fluorophotometry, and artificial intelligence-based diagnostic systems are creating new opportunities for market participants.

With the market projected to increase from US$58.3 million in 2020 to US$99.4 million by 2031, continued investment in accurate, efficient, non-invasive, and technology-driven diagnostic solutions is expected to remain central to the evolution of dry eye disease diagnosis in the United States.